Italy has approved the temporary distribution of GlaxoSmithKline and partner Vir Biotechnology’s COVID-19 antibody treatment sotrovimab, as reported by Fidelity.
The health ministry said the therapy can be distributed until January 31, 2022, adding the authorisations for all the other monoclonal treatments currently in use in the country had also been extended to the same date.
Rome has approved monoclonal antibody therapies from Eli Lilly and Regeneron Pharmaceuticals.
The European Union's drug regulator in May backed the use of sotrovimab to treat patients who are at risk of severe disease and do not need supplemental oxygen above the age of 12.
To read more NewsPoints articles, click here.